Coming off GLP-1 medications: what actually happens, and how to plan it

If you're thinking about stopping Mounjaro or Wegovy, you deserve an honest account of what to expect. Not a list of tips that implies willpower is the main variable. Not a scare story designed to keep you on the medication forever. The actual evidence, clearly explained.

What the data actually shows

The evidence on what happens after stopping GLP-1 medications is now robust and consistent. The headline finding from a 2026 BMJ meta-analysis of 37 studies covering over 9,000 people is uncomfortable but important:

Several specific trial findings are worth understanding:

• The STEP 1 trial extension found that one year after stopping semaglutide 2.4mg, participants had regained approximately two-thirds of the weight they'd originally lost
• Cardiometabolic improvements — blood pressure, HbA1c, cholesterol, triglycerides — also reversed after stopping, returning toward baseline at a similar rate to weight
• In the SURMOUNT-4 trial, people who stopped tirzepatide after 36 weeks regained weight significantly faster than those who continued, confirming the pattern applies to both medications
• Weight regain after GLP-1 cessation is approximately four times faster than weight regain after stopping a behavioural weight management programme

Why regain happens so quickly

The speed of weight regain surprises people, but it's biologically predictable. GLP-1 medications work by persistently activating receptors that signal fullness and suppress appetite. When you stop, this suppression ends — and the underlying biological drivers of appetite return, often fully, within weeks.

This is fundamentally different from a dietary intervention, where the new eating patterns you've established may partly persist. With GLP-1 treatment, the appetite suppression is pharmacological rather than behavioural. The medication does the work; habits play a secondary role. When the medication stops, the primary driver of your reduced appetite disappears.

What makes this faster than behavioural approaches:

• Gastric emptying returns to its pre-treatment rate relatively quickly — food moves through faster, fullness signals arrive later
• The neural pathways that generate food cravings — suppressed while on medication — reactivate
• Energy expenditure may also reduce, as the metabolic effects of the medication fade
• Behavioural programmes, even imperfectly maintained, leave some lasting changes in food relationship and habits. Medication-led appetite suppression typically doesn't

Common reasons people stop — and what each means

Does tapering help?

This is the question most people ask, and the honest answer is: we don't have strong trial evidence for tapering. There is no established, clinician-approved tapering protocol for GLP-1 medications — unlike, for example, antidepressants or corticosteroids where tapering protocols are well-defined.

What the evidence suggests:

• Tapering may slow the initial rate of regain — reducing to a lower dose rather than stopping abruptly gives the body a more gradual transition back to baseline receptor activation. This is physiologically plausible.
• It probably doesn't change the final outcome — the meta-analysis data suggests that by 18 months post-cessation, most people have returned to baseline weight regardless of how they stopped. Tapering may soften the trajectory, not change the destination.
• Most clinicians who do recommend tapering suggest stepping down by one dose level per month — so from 10mg Mounjaro to 7.5mg to 5mg to 2.5mg, then stopping. This gives several months of gradual reduction.
• The alternative view — that tapering just delays the inevitable and may be better directed at building lifestyle habits during the taper period — is also clinically reasonable.

How to stop — an honest protocol

There's no single right way, but here's a framework that most clinicians would consider sensible:

What actually slows regain

The evidence on what helps after stopping is honest in its limitations: most lifestyle interventions slow but don't prevent regain. The biology is strong. But meaningful slowing is still worth pursuing.

What the research and clinical experience suggests helps:

• High protein intake — protein is the most satiating macronutrient and helps preserve muscle mass during weight changes. Prioritising protein at every meal — 25–35g per meal — is the single most evidence-backed dietary intervention for weight maintenance after GLP-1 cessation
• Structured meal timing — not snacking between meals, eating at consistent times, and avoiding the constant grazing that GLP-1 medications naturally suppress. Building this as a habit before stopping means it partially persists
• Resistance training — muscle mass is preserved better with strength training than cardiovascular exercise during weight regain. Muscle is metabolically active; more muscle means higher baseline energy expenditure
• Fibre-rich eating — high-fibre foods slow digestion and provide some of the satiety effect the medication was providing pharmacologically
• Regular weight monitoring — weekly weigh-ins, tracked, so you have data not impressions. The aim isn't to panic at every fluctuation but to catch an upward trend early

Restarting after a break

Many people stop and restart — sometimes multiple times. This is neither unusual nor problematic from a clinical standpoint. There's no evidence that stopping and restarting reduces the medication's effectiveness, and no established maximum number of treatment courses.

What you need to know about restarting:

• Retitration is typically required — if you've been off for more than 4 weeks (Mounjaro) or 5 weeks (Wegovy), you should restart from the lowest dose and re-titrate. This is to allow your body to readjust and minimise side effects.
• Some prescribers allow accelerated retitration — if you've been off for a shorter period or if your previous tolerance was excellent, your prescriber may allow you to restart at a slightly higher dose than 2.5mg. This is a clinical judgement, not a standard protocol.
• Your response may differ from first time — some people find the medication equally effective on restart; others find it takes longer to see the same results. The data on repeat courses is limited.
• Maintain your provider relationship — restarting is easier with an existing prescriber than starting from scratch, particularly around dose transfer documentation.

Thinking about long-term use honestly

The question of whether to stop is ultimately a question about what you're trying to achieve and whether ongoing treatment is the right tool for it.

For people with significant obesity and health risks — cardiovascular disease, type 2 diabetes, sleep apnoea, MASH — indefinite treatment may be the right clinical answer. The health benefits during treatment are real and meaningful, and the risks of stopping (weight regain, return of metabolic risk) may outweigh the costs of continuing.

For people who started treatment at lower BMI, reached their goal weight, and are now maintaining — the calculation is different. The question is whether the cost, the weekly injection, and the ongoing prescriber relationship are worth the benefit of maintained weight at their specific health risk level.

Neither of these is a simple question, and the right answer varies by person. What the evidence doesn't support is the idea that GLP-1 treatment is a time-limited course that produces permanent results. It isn't. The honest framing is: these are effective management tools for a chronic condition, and stopping them typically means the condition returns.

Common questions